Insulet (NASDAQ:PODD) Price Target Cut to $315.00 by Analysts at Truist Financial

Insulet (NASDAQ:PODD) had its price target decreased by Truist Financial from $360.00 to $315.00 in a research note issued to investors on Wednesday, MarketBeat.com reports. Truist Financial currently has a buy rating on the medical instruments supplier’s stock.

Several other research firms have also recently weighed in on PODD. Stifel Nicolaus cut their target price on shares of Insulet from $370.00 to $350.00 and set a “buy” rating for the company in a research note on Wednesday, February 4th. JPMorgan Chase & Co. cut their target price on shares of Insulet from $415.00 to $340.00 and set an “overweight” rating for the company in a research note on Thursday, February 19th. Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a research note on Thursday, January 22nd. Barclays reissued an “underweight” rating and issued a $286.00 price objective on shares of Insulet in a research note on Thursday, February 19th. Finally, Raymond James Financial dropped their price objective on shares of Insulet from $385.00 to $355.00 and set an “outperform” rating for the company in a research note on Thursday, February 19th. Nineteen investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $334.38.

Insulet Stock Performance

PODD opened at $202.50 on Wednesday. The stock has a market capitalization of $14.03 billion, a price-to-earnings ratio of 57.86, a PEG ratio of 1.21 and a beta of 1.47. The company has a fifty day moving average of $229.10 and a 200 day moving average of $277.01. Insulet has a fifty-two week low of $194.61 and a fifty-two week high of $354.88. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.07. The company had revenue of $783.80 million during the quarter, compared to analysts’ expectations of $768.31 million. Insulet had a net margin of 9.12% and a return on equity of 24.90%. Insulet’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period last year, the company posted $1.15 earnings per share. As a group, sell-side analysts forecast that Insulet will post 3.92 earnings per share for the current fiscal year.

Insider Activity at Insulet

In other Insulet news, Director Michael R. Minogue acquired 2,030 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was acquired at an average cost of $246.23 per share, with a total value of $499,846.90. Following the purchase, the director directly owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. This represents a 13.14% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.39% of the stock is owned by insiders.

Institutional Investors Weigh In On Insulet

Institutional investors have recently made changes to their positions in the company. Larson Financial Group LLC lifted its holdings in shares of Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Insulet in the 4th quarter worth about $26,000. True Wealth Design LLC lifted its holdings in shares of Insulet by 288.0% in the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 72 shares during the last quarter. DV Equities LLC bought a new stake in shares of Insulet in the 4th quarter worth about $28,000. Finally, Elyxium Wealth LLC bought a new stake in shares of Insulet in the 4th quarter worth about $28,000.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Truist cut its price target to $315 from $360 but kept a Buy rating, noting continued conviction in Insulet’s growth; the new target still implies meaningful upside from current levels. Truist cuts price target
• Positive Sentiment: BTIG issued a Buy on PODD (coverage reported by The Globe and Mail), which supports near-term investor interest despite other downward PT revisions. BTIG Buy
• Neutral Sentiment: Evercore/ISI reiterated an Outperform/Outperform-equivalent rating but lowered its target to $240 from $340 — a signal that fundamental confidence remains but near-term expectations have been dialed back. Evercore reiterates Outperform
• Neutral Sentiment: Price/value commentary (Zacks, InsiderMonkey) highlights PODD as a value/oversold candidate on some metrics (ROE growth, valuation comparisons) — these analyses can attract bargain hunters but aren’t immediate catalysts. Zacks comparison
• Negative Sentiment: Insulet disclosed a voluntary medical-device correction for Omnipod 5 insulin pods due to a design defect that can cause insulin leakage; the recall/ correction has been tied to multiple serious adverse events and triggered an initial share decline. Device correction and investor alert
• Negative Sentiment: Multiple law firms (Pomerantz, Levi & Korsinsky) have launched investor investigations or potential class-action activity related to the Omnipod issue, increasing legal and reputational risk and creating potential financial exposure. Pomerantz investigation
• Negative Sentiment: Recent analyst notes and market pieces (including coverage reporting downgrades/pessimistic forecasts) have pushed the stock to a new 1-year low in some reports, amplifying downward pressure and volatility. Analyst downgrade / new low Pessimistic forecast

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.